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Abstract 
Severe hypercalcaemia during pregnancy is rare and most cases are secondary to 
hyperparathyroidism. This is the first report of a parathyroid hormone related protein 
(PTHrP) secreting neuroendocrine tumour of the pancreas manifesting with severe 
hypercalcaemia during pregnancy. Measurement of PTHrP was useful in both the diagnosis 
and follow up of our patient and should be considered in the diagnostic workup of patients 
with unexplained hypercalcaemia. A raised PTHrP concentration is a strong indicator of 
malignancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe hypercalcaemia is rare during pregnancy. Most cases are due to hyperparathyroidism 
but there are fewer than 150 patients reported in world literature.
1
 There have been two 
reports of the milk alkali syndrome
2
 and four reported cases of parathyroid carcinoma during 
pregnancy.
3
 Other cases of malignancy related hypercalcaemia in pregnancy are very rare. 
Parathyroid hormone related protein (PTHrP) was first isolated in 1987 from cancer cell lines 
and a tumour associated with hypercalcaemia, and is now considered to be the main mediator 
of humoral hypercalcaemia of malignancy.
4,5
 The placenta (during pregnancy) and mammary 
glands (postpartum) are important physiological sources of PTHrP.
6
 
We report a case of extreme hypercalcaemia manifesting during pregnancy. The 
hypercalcaemia was associated with raised levels of 1,25-dihydroxyvitamin D3(1,25(OH)2D3) 
and was eventually found to be due to a PTHrP secreting pancreatic neuroendocrine tumour. 
 
CASE REPORT 
A 25 year old woman presented at 29 weeks’ gestation with altered consciousness, headache, 
hypertension and proteinuria, and was initially thought to have pre-eclampsia. She was noted 
to have taken 1 g of mefenamic acid in divided doses during the two days before 
presentation. 
Her initial investigations showed a serum calcium adjusted for albumin of 5.9 mmol/l 
(reference range 2.2–2.6). A retrospective measurement of calcium at 19 weeks’ gestation 
was obtained at 2.33 mmol/l. Her serum phosphate was raised at 2.07 mmol/l (reference 
range 0.7–1.2), probably as a result of her renal impairment. She had renal failure with a 
serum creatinine of 328 μmol/l (reference range 60–110) and her 24 hour urinary protein was 
9.09 g. Parathyroid hormone was undetectable using a two site immunoradiometric assay 
(Diagnostic Product Corporation Immulite, Los Angeles USA). 
Her early management consisted of an emergency caesarean section followed by transfer to 
the intensive therapy unit. She was given five intravenous doses of pamidronate 15 mg twice 
daily. In the postpartum period calcium decreased rapidly after pamidronate and she required 
calcium supplements for one month. The calcium decreased to a nadir of 1.9 mmol/l then 
subsequently steadily increased to 2.68 mmol/l at 12 months and 2.76 mmol/l at 15 months. 
Her renal function improved rapidly with serum creatinine decreasing to 99 μmol/l at 10 days 
but the proteinuria took six months to normalise. 
Serum parathyroid hormone concentrations were undetectable on three occasions between 
three and 12 months postpartum while the patient remained significantly hypercalcaemic at 
the time (fig 1). Measurement of serum vitamin D metabolites showed a normal 25-
hydroxyvitamin D3 (25(OH)D3) at 19 nmol/l (reference range 15–100) with a 
1,25(OH)2D3 level in the upper end of the normal range at 97 nmol/l (reference range 20–
120). Because of these results, extrarenal vitamin D3 production secondary to granulomatous 
disease or lymphoma was considered as a possible cause of the hypercalcaemia. Serum 
angiotensin converting enzyme was normal at 38 U/l (reference range 8–52U/l) and chest 
radiography did not suggest sarcoidosis. An ultrasound of her abdomen was normal and 
isotope bone scans performed at one and eight months postpartum were both normal. A 
myeloma screen was negative. Transilical bone biopsy showed increased osteoclastic activity 
but no evidence of lymphoma. A whole body computed tomogram at 14 months postpartum 
showed a 9 cm pancreatic mass and an ultrasound guided fine needle aspiration of this mass 
showed results consistent with a neuroendocrine tumour. An octreoscan showed increased 
uptake in the region of the distal pancreas with no evidence of metastases. 
A vitamin D challenge test was performed by administering 2000 IU of 25(OH)D3 for 10 
days with alternate day measurement of calcium and vitamin D metabolites (see table 1). This 
suggested inappropriate activation of vitamin D since the levels of 1,25(OH)2D3 remained 
raised despite the hypercalcaemia. PTHrP (Diasorin Stillwater, USA) measured immediately 
and two months postpartum was 3.3 pmol/l and 3.9 pmol/l (reference value <0.5 pmol/l). A 
somatostatin challenge test was performed using octreotide 100 μg subcutaneously and the 
PTHrP decreased from 3.3 to 2.1 pmol/l in one hour followed by normalisation of the serum 
calcium. 
The patient underwent laparotomy and removal of the pancreatic mass in November 1998. 
For effective tumour removal a splenectomy was also required. Histology and PTHrP 
immunostaining showed a neuroendocrine tumour with positive immunocytochemical 
staining using a PTHrP antibody. Staining for the 1α-hydroxylase enzyme was negative. 
Postoperatively serum calcium (fig 1) and PTHrP levels normalised and remained normal 
after two years of follow up. Gut hormones were normal and vitamin D metabolites returned 
to reference values. 
The baby was also noted to have hypercalcaemia immediately after birth (calcium 3.03 
mmol/l) but subsequently became hypocalcaemic over the next two days (calcium 1.59 
mmol/l) and required calcium supplementation for about a month. The baby had other 
problems related to prematurity and required mechanical ventilation for four days along with 
surfactant. On discharge from the neonatal unit two months after the delivery all metabolic 
problems had settled, and on subsequent follow up a diagnosis of mild asymmetric cerebral 
palsy was made which was felt to be mainly due to prematurity. 
DISCUSSION 
This is the first reported case of a PTHrP secreting pancreatic neuroendocrine tumour 
manifesting with a hypercalcaemic crisis during pregnancy. The combination of non-steroidal 
anti-inflammatory drugs with hypercalcaemia combined to produce a severe acute renal 
failure and acute deterioration leading to her presentation during pregnancy. 
The role of vitamin D metabolites in the pathogenesis of humoral hypercalcaemia of 
malignancy is a controversial area. While PTHrP binds to the parathyroid hormone type I 
receptor and mimics virtually all the biological actions of parathyroid hormone,
7
 serum levels 
of 1,25(OH)2D3 in humoral hypercalcaemia of malignancy are frequently suppressed and 
much lower than in primary hyperparathyroidism.
8–10
 This has led many workers to suggest 
that PTHrP does not stimulate renal 1α-hydroxylase activity in patients with humoral 
hypercalcaemia of malignancy.
11,12
 However Schweitzer et al,
12
 Sato and Takahashi,
13
 and 
Ralston et al
8
have commented on the fact that 1,25(OH)2D3 levels are frequently not 
suppressed in humoral hypercalcaemia of malignancy, consistent with a stimulatory effect of 
PTHrP on 1α-hydroxylase activity. In keeping with this hypothesis, serum 
1,25(OH)2D3 levels are increased in various animal models of PTHrP mediated humoral 
hypercalcaemia of malignancy.
14,15
 Reasons that have been put forward to explain the lower 
levels of 1,25(OH)2D3 in humoral hypercalcaemia of malignancy compared with primary 
hyperparathyroidism include the fact that humoral hypercalcaemia of malignancy is often 
associated with very severe hypercalcaemia and renal failure which can suppress 1α-
hydroxylase activity
16
 and that many patients with humoral hypercalcaemia of malignancy 
have low levels of the precursor 25(OH)D3.
8
 
Inappropriate activation of 1,25(OH)2D3 production was found in our patient, which almost 
certainly represented a stimulatory effect of PTHrP on renal 1α-hydroxylase activity. 
Increased production of 1,25(OH)2D3 by the tumour itself was excluded by the fact that we 
found no evidence of 1α-hydroxylase activity within the tumour. 
The reduction in PTHrP and calcium after administration of the somatostatin analogue 
octreotide is interesting and has been documented previously in other neuroendocrine 
tumours.
17,18
 This may have therapeutic potential if surgical clearance is not possible. PTHrP 
measurements were useful in this case in clarifying the diagnosis of the hypercalcaemia and 
also in follow up as the PTHrP remained reassuringly normal over two years of follow up. 
PTHrP measurement should be considered in the diagnostic workup of hypercalcaemia of 
obscure aetiology. A raised PTHrP concentration is strong evidence for the presence of 
malignancy. 
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Figure 1 
Summary of PTHrP (reference value <0.5 pmol/l) and serum calcium (reference range 2.2–
2.6 mmol/l) concentrations over two years (PAM, pamidronate). 
 
Table 1 
Vitamin D challenge test (performed by administering 2000 IU of 25-hydroxyvitamin 
D3(25(OH)D3) for 10 days with alternate day measurement of calcium and vitamin D 
metabolites). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab.1 
Day 
Calcium (RR 2.2–
2.6 mmol/l) 
25(OH)D3(RR 15–
100 pmol/l) 
1,25(OH)2D3(RR 20–
120 pmol/l) 
−2 2.13 62 160 
0 2.66 41 239 
2 2.89 66 208 
4 2.97 80 187 
6 2.68 75 212 
8 3.08 85 205 
10 3.15 97 231 
1,25(OH)2D3, 1,25-dihydroxyvitamin D3; RR, reference range. 
 
 
 
 
 
 
 
